Smith+Nephew (NYSE: SNN) reported revenue growth across its operating segments for the fourth quarter of fiscal 2025. The medical technology company also issued guidance for fiscal 2026.
- Fourth-quarter revenue increased 8.3% YoY to $1.70 billion, on a reported basis; underlying revenue growth was 6.2%
- Orthopaedics and Sports Medicine & ENT revenues rose 9.8% and 9.5%, respectively, on a reported basis
- Revenues of the Advanced Wound Management division rose 5.3% annually
- For 2026, management targets further progress in revenue growth and trading profit; it sees sustained strong cash generation
- Full-year underlying revenue growth is expected to accelerate further to around 6%
- In fiscal 2026, trading profit growth, on an organic basis, is expected to be around 8%
- The company is looking for a free cash flow of around $800 million for fiscal 2026